Putting insulin resistance into context by dietary reversal of type 2 diabetes
R Taylor1

Abstract

It has long been assumed that type 2 diabetes is caused by the combined effects of insulin resistance and loss of pancreatic islet beta cells. Much therapeutic effort has been directed towards decreasing insulin resistance even though results have been generally disappointing. Now that type 2 diabetes can be understood as a simple reversible condition, its component parts can be examined during the period of return to normal glucose tolerance.

Keywords: diet, insulin resistance, type 2 diabetes

Declaration of interests: No conflict of interests declared

What is insulin resistance?

Any individual will respond to a fixed dose of insulin in a manner depending upon the degree of sensitivity to insulin. At the one end of the spectrum, slim athletic people are likely to be very sensitive to insulin, whereas obese inactive people are likely to be relatively insensitive, or insulin resistant. Different tissue exhibit different sensitivity to insulin, but the phrase ‘insulin resistance’ has become synonymous with results of euglycemic hyperinsulinemic clamp studies. These tests predominantly measure muscle insulin sensitivity.1

Insulin resistance in muscle is the earliest indicator of risk of future development of type 2 diabetes.2 It has been assumed that reversing the insulin resistance would considerably improve the level of blood glucose control in established type 2 diabetes, and much therapeutic effort has been directed at the targeted insulin resistance. However, even vigorous exercise training produces only a modest effect on blood glucose control.3 Similarly, drugs developed specifically to improve insulin resistance – thiazolidinediones – produce only modest benefit.4

It is the insulin sensitivity of a different organ which is most closely associated with control of fasting plasma glucose. The liver is responsible for continuous production of glucose. This is essential to survival as the brain requires a continuous supply of glucose for its energy needs in everyday life. Especially during the overnight period, life continues only because the liver produces around 10 g of glucose per hour.5 This is regulated by insulin, and hence any degree of insulin resistance in this process would lead to increased production of glucose. Indeed, fasting plasma insulin is typically raised in type 2 diabetes, but nonetheless the liver produces around 15 g of glucose per hour.6

Predictions of the twin cycle hypothesis

In 2008 it was possible to bring together information on control of liver glucose production and beta cell function to postulate the events leading to the onset of type 2 diabetes (Figure 1).7

Type 2 diabetes only occurs after a decade or more of positive energy balance. Any fat in excess of daily requirement for oxidation can be stored in subcutaneous tissue but any excess carbohydrate can be handled only by one pathway: conversion to triglyceride. This happens solely in the liver and is promoted by the presence of high insulin levels. The pathway is not subject to insulin resistance, so individuals who are relatively insulin resistant have modestly raised plasma insulin levels and will be able to convert carbohydrate into liver fat more readily. The first step in the twin cycle hypothesis is that the levels of fat inside the liver gradually rise and this brings about increasing liver insulin resistance. In order to control the output of glucose by the liver, plasma insulin levels must rise. It creates a vicious cycle leading to steadily increasing liver fat levels.

The higher the liver fat level, the higher the rate of export of triglyceride to the rest of the body. This is done in the form of

1Professor of medicine and metabolism and Director, magnetic resonance Centre, Campus for Ageing & Vitality, Newcastle University, Newcastle upon Tyne, UK
During chronic positive calorie balance, any excess carbohydrate must undergo de novo lipogenesis. There is no other available pathway, and it can only occur in the liver. This particularly promotes fat accumulation in the liver. As insulin stimulates de novo lipogenesis, individuals with a degree of insulin resistance (determined by family or lifestyle factors) will increase liver fat more readily than others due to the higher plasma insulin levels. The increased liver fat will cause relative resistance to suppression of hepatic glucose production by insulin. Over many years, this will bring about a small increase in fasting plasma glucose level, and hence increased basal insulin secretion rates. The consequent hyperinsulinaemia will further enhance the conversion of excess calories into liver fat. A vicious cycle of hyperinsulinaemia and blunted suppression of hepatic glucose production becomes established. Fatty liver leads to increased export of VLDL triglyceride which will increase fat delivery to the islets of the pancreas along with all other tissues. This process is further stimulated by elevated plasma glucose levels. Excess fatty acid availability in the pancreatic islet will bring about beta-cell de-differentiation and impair the acute insulin secretion in response to ingested food. At a certain level of fatty acid exposure, postprandial hyperglycaemia will develop. The hyperglycaemia will further increase insulin secretion rates and hepatic lipogenesis, spinning the liver cycle faster and promoting the pancreas cycle. Eventually the fatty acid and glucose inhibitory effects on the islets reach a trigger level leading to a relatively sudden onset of clinical diabetes.

**Figure 1** The twin cycle hypothesis

[Diagram showing the twin cycle hypothesis]

But what happened to muscle insulin resistance during the disappearance of the type 2 diabetic state?

Euglycemic hyperinsulinemic clamp studies during the Counterpoint study allowed measurement of muscle insulin resistance, separate from that of the liver. No change in muscle insulin resistance occurred despite return to the non-diabetic state.

Longer term observations

It was necessary to conduct a further study to observe the long term physiology after reversal of type 2 diabetes. The Counterbalance study was designed to follow up individuals for six months after initial weight loss. It confirmed the findings of the Counterpoint study. In particular it showed that there was no change in muscle insulin resistance after reversal of type 2 diabetes, and only a trivial improvement over the six months of weight maintenance and continuation of non-diabetic glucose control.

The essential nature of type 2 diabetes

It can now be seen that muscle insulin resistance is a factor which expedites the accumulation of liver fat during the phase of developing the condition. Muscle insulin resistance itself is not relevant to maintenance of the diabetic state.
Insulin resistance in context

Although insulin resistance is associated with physical inactivity, dyslipidaemia and increased risk of macrovascular disease, it is important to set in context its role in the development of type 2 diabetes.

Box 1 Muscle insulin resistance

- Mice totally lacking muscle receptors do not develop diabetes\(^a\)
- People with PP1R2A variant of glycogen synthase cannot store glucose as glycogen and muscle – yet have normal glucose tolerance\(^b\)
- 8% weight loss in type 2 diabetes markedly improved glucose control but with no change in muscle insulin resistance\(^c\)
- 15% weight loss normalises glucose homeostasis in type 2 diabetes with no decrease in muscle insulin resistance\(^d\)

Given that the degree of insulin resistance exhibited by people with type 2 diabetes overlaps entirely with that of the non-diabetic majority population,\(^e\) muscle insulin resistance can be seen not as a disease state per se, but as an individual characteristic which affects risk. It does not dictate pathogenesis.

The good news for people with type 2 diabetes is that they have a potentially reversible metabolic condition. Large numbers of individuals who are strongly motivated have now returned their metabolic state to normal, and are off all medication.\(^f\) While these insights allow motivated people to make a profound difference to their own health, acquiring evidence upon which a change of guideline advice can be based is very different. It remains to be demonstrated how this can be applied to the management of all people with type 2 diabetes. A large study in primary care will test the practical applicability of the approach by randomisation to either weight loss plus a behavioural weight maintenance programme or to best care according to current guidelines.\(^g\) DiRECT (Diabetes Remission Clinical Trial) will report the one year outcomes this year.

References


